Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Benefit and Prior Authorization Information for Allogeneic Processed Thymus Tissue-agdc (Rethymic)

Last updated on

Effective for dates of service on or after July 1, 2026, allogeneic processed thymus tissue-agdc (Rethymic) is a benefit of Texas Medicaid when it is submitted on a claim with procedure code J3590. Prior authorization will be required beginning September 1, 2026.

Allogeneic processed thymus tissue-agdc (Rethymic) is indicated for immune reconstruction in pediatric clients with congenital athymia.

Allogeneic processed thymus-agdc (Rethymic) is limited to one surgical procedure per lifetime.

Prior Authorization Requirements

Providers must submit prior authorization requests for allogeneic processed thymus tissue-agdc (Rethymic) on a Special Medical Prior Authorization (SMPA) Request Form.

The Texas Medicaid & Healthcare Partnership (TMHP) may approve prior authorization for allogeneic processed thymus tissue-agdc (Rethymic) for clients who meet the following requirements:

  • The client is 18 years of age or younger.
  • The client has a diagnosis of congenital athymia that is confirmed by flow cytometry (diagnosis code D821).
  • Severe combined immunodeficiency (SCID) has been conclusively ruled out.
  • An anti-human leukocyte antigen (HLA) antibody test was conducted before the start of treatment. If the client tests positive for anti-HLA antibodies, they must receive allogeneic processed thymus tissue-agdc (Rethymic) from a donor who does not express HLA alleles.
  • The prescriber must attest that the benefits and risks of treatment have been evaluated for clients with preexisting cytomegalovirus (CMV) infection or renal impairment.
  • The client has not previously received thymus tissue transplantation.

Required Monitoring Parameters

After allogeneic processed thymus tissue-agdc (Rethymic) implantation, providers must monitor the client for the following:

  • The risk of developing graft-versus-host disease (GVHD)
  • The possibility of developing autoimmune or lymphoproliferative disorders, which is monitored through complete blood counts (CBC) with differential, liver enzymes, serum creatinine, urinalysis, and thyroid function
  • Renal impairment or failure
  • The occurrence of an infectious disease, as these may develop because allogeneic processed thymus tissue-agdc (Rethymic) is derived from human tissue

For more information, call the TMHP Contact Center at 800-925-9126.

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.